Aug 13, 2020
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Jun 13, 2020
Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer
Jun 12, 2020
QBioMed to Support and Exhibit at Living Beyond Breast Cancer 2020 Virtual Conference on June 13-14, 2020
May 29, 2020
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020
May 27, 2020
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
May 26, 2020
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
May 05, 2020
Theresa's Research Foundation Launches PAVE
Apr 16, 2020
Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment
Mar 24, 2020
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
Feb 05, 2020
Imagion Biosystems Appoints Vice President Clinical & Regulatory Affairs
Jan 15, 2020
Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease
Dec 30, 2019
METAvivor Announces 2019 Grant Awards For Metastatic Breast Cancer Research
Dec 09, 2019
New Menarini CELLSEARCH Studies to be Presented at San Antonio Breast Cancer Symposium
Dec 05, 2019
Epic Sciences to Present New Data Showing Feasibility of its Liquid Biopsy Test in Breast Cancer
Dec 02, 2019
Metastatic Breast Cancer Alliance Announces Release of MBC Connect 2.0
Nov 29, 2019
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
Nov 28, 2019
Health Canada approves Kadcyla® (trastuzumab emtansine) for the treatment of HER2-positive early breast cancer after surgery(1)
Nov 21, 2019
Patient First staff rallies around colleague battling breast cancer
Nov 20, 2019
Phoenix Molecular Designs Initiates its Phase 1/1b Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer
Nov 20, 2019
Biovica's DiviTum Validated as a Dynamic Biomarker in Metastatic Breast Cancer in Collaboration With Institut Curie, Paris